The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

IlDong Pharmaceutical Co Ltd400 enrolled

Overview

To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

400

Conditions

Hypercholesterolemia

Interventions

Rosuvastatin/EzetimibeDRUG

Rosuvastatin 5mg

Eligibility

Sex: ALLMin age: 19 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypercholesterolemic patient Exclusion Criteria: * Has history of hypersensitivity to HMG-CoA reductase inhibitor and Ezetimibe

Locations (1)

Gil Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Percent change from baseline to 8 week in LDL-Cholesterol

Time frame: baseline and 8 week

Secondary Outcomes

Percent change from baseline to 4 week in LDL-Cholesterol

Time frame: baseline and 4 week

Central Contacts

Min-Hee Kwon

CONTACT

02-526-3379 minhee@ildong.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.